The pharmaceutical industry continues to undergo a radical transformation, primarily driven by the integration of artificial intelligence (AI) in drug research and development (R&D). Sanofi, as a major player, illustrates this trend by optimizing drug target discovery through AI. Simultaneously, Amgen, in partnership with NVIDIA, explores generative AI to transform human data analysis and accelerate drug discovery. This dynamic is reinforced by strategic collaborations, such as that between Pfizer and an Austrian institute, aimed at developing innovative AI models. However, these advancements are accompanied by regulatory and ethical challenges, necessitating a rapid adaptation of legislative frameworks.
Débloquez l'Analyse Complète
Accédez instantanément à nos insights exclusifs générés par IA, basés sur l'agrégation de centaines de sources sectorielles.
